Retatrutide in Canada: Understanding the Clinical Evidence Behind an Investigational Triple-Hormone Receptor Agonist

Publication Type: Consumer Research Brief
Jurisdiction: Canada
Regulatory Reference: Health Canada
Evidence Base: Phase 2 and Phase 3 Clinical Trial Data
Date: 2026

Abstract

Retatrutide (LY3437943) is an investigational, once-weekly injectable peptide. It is the first molecule in its class to simultaneously activate three hormone receptors — the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon (GCG) receptor — earning it the designation of a triple-hormone receptor agonist. As of the date of this article, retatrutide has not been authorised by Health Canada for sale or use as a marketed therapeutic treatment for any medical condition. All evidence discussed herein is derived exclusively from peer-reviewed clinical trial publications and registered trial results.

This article summarises the current body of clinical trial evidence for retatrutide, focusing on three headline findings: (1) a mean body-weight reduction of 24.2% at 48 weeks in the 12 mg group of the Phase 2 obesity trial compared to 2.1% in the placebo group [1]; (2) a maximum glycated haemoglobin (HbA1c) reduction of approximately 2.2 percentage points in the Phase 2 diabetes trial [2]; and (3) marked reductions in liver-fat content observed in a Phase 2a metabolic-dysfunction-associated steatotic liver disease (MASLD) substudy [3]. The article also addresses the known and theoretical risks, side effects, and anticipated contraindications identified across trials to date, and places these findings within the context of ongoing Phase 3 clinical development. A 10 mg vial is a product-strength reference only; it does not represent a validated, evidence-based therapeutic dose and should not be interpreted as such.

1. Introduction

Obesity is among the most pressing and complex chronic health challenges facing Canadians today. According to the Public Health Agency of Canada, approximately 26.8% of Canadian adults live with obesity, and an additional 36.3% are classified as overweight — together representing nearly two-thirds of the adult population [4]. Obesity is a recognised risk factor for type 2 diabetes, cardiovascular disease, fatty liver disease, obstructive sleep apnoea, osteoarthritis, and numerous other conditions that reduce quality of life and life expectancy.

For decades, the pharmacological treatment of obesity was limited to a small number of options with modest efficacy and significant tolerability limitations. The emergence of GLP-1 receptor agonist therapy — particularly semaglutide and tirzepatide — represented a turning point in metabolic medicine, demonstrating sustained weight losses of 15–22% of body weight in rigorous clinical trials. Retatrutide now represents what researchers believe may be the next significant leap forward: a molecule engineered to activate not one or two, but three distinct hormonal pathways simultaneously.

However, it is critical that Canadian consumers and patients understand the distinction between what the clinical trial record currently demonstrates and what has been formally reviewed, approved, and authorised for therapeutic use in Canada. Retatrutide is an investigational drug. It is not available through Canadian pharmacies as an authorised treatment. This article is intended to be educational — to help readers understand what the peer-reviewed science says, what it does not yet say, and what regulatory steps remain before any such authorisation could occur.

2. Mechanism of Action: How Retatrutide Works

2.1 The Three Receptor Targets

To understand why researchers are excited about retatrutide, it is helpful to understand the three hormonal systems it engages.

GLP-1 (Glucagon-Like Peptide-1): GLP-1 is a gut-derived hormone released after eating. It stimulates insulin secretion in a glucose-dependent manner (meaning it only triggers insulin when blood glucose is elevated), suppresses glucagon release, slows gastric emptying, and — critically — signals to the brain's appetite centres to reduce hunger and food intake. GLP-1 receptor agonism is the core mechanism shared by semaglutide and tirzepatide, two drugs currently authorised in Canada.

GIP (Glucose-Dependent Insulinotropic Polypeptide): GIP is another gut hormone that enhances insulin secretion after meals and may also play a role in fat metabolism and the central regulation of energy balance. GIP receptor agonism is part of tirzepatide's mechanism, and is believed to complement GLP-1 agonism by improving tolerability and enhancing metabolic outcomes.

Glucagon (GCG): Glucagon is a hormone produced by the pancreas that raises blood glucose by stimulating the liver to release stored glucose (glycogen). At first consideration, activating the glucagon receptor in someone trying to lose weight might seem counterproductive — but at the controlled, incremental activation levels achieved by retatrutide, glucagon receptor agonism is believed to increase energy expenditure, promote fat burning, and drive reductions in liver-fat content. The glucagon component is considered a key differentiator of retatrutide from its predecessors [1, 3].

2.2 The Rationale for Triple Agonism

Each of these three pathways contributes a distinct and complementary mechanism for weight management and metabolic improvement. GLP-1 and GIP agonism work together to suppress appetite and improve glycaemic control, while glucagon receptor agonism adds a layer of increased energy expenditure and hepatic fat mobilisation. Researchers hypothesise that the combination of all three mechanisms may produce weight-loss and metabolic effects that exceed what any single- or dual-receptor approach can achieve [1, 5].

Retatrutide is engineered as a single molecule — not a combination of separate drugs — with a precisely calibrated affinity for each receptor. This design is intended to produce coordinated, balanced activation across all three pathways through a single once-weekly subcutaneous injection.

3. Clinical Trial Evidence: Key Findings

It is essential to note before reviewing these findings that all data described below come from Phase 2 and Phase 3 clinical trials. These trials are carefully designed scientific experiments conducted under regulatory oversight. They establish whether a drug shows promise and define its likely benefit-risk profile, but they do not constitute regulatory approval. Health Canada's authorisation process involves an independent and rigorous review of all such data before a drug may be marketed or prescribed in Canada. Retatrutide has not yet completed that review process.

3.1 Phase 2 Obesity Trial (Jastreboff et al., New England Journal of Medicine, 2023)

The landmark Phase 2 obesity trial, published in the New England Journal of Medicine in July 2023, enrolled 338 adults with obesity or overweight who did not have type 2 diabetes [1]. Participants were randomised to receive one of four doses of retatrutide (1 mg, 4 mg, 8 mg, or 12 mg) or placebo, administered once weekly via subcutaneous injection, over 48 weeks. The trial was conducted at sites in the United States.

Primary Efficacy Findings

The results were striking across all active doses:

  • 1 mg group: Mean weight reduction of approximately 8.7% from baseline

  • 4 mg group: Mean weight reduction of approximately 17.5% from baseline at 24 weeks

  • 8 mg group: Mean weight reduction of approximately 22.8% from baseline at 48 weeks

  • 12 mg group: Mean weight reduction of 24.2% from baseline at 48 weeks

  • Placebo group: Mean weight reduction of 2.1% from baseline at 48 weeks [1]

To put 24.2% in concrete terms: for a person weighing 100 kg (approximately 220 lbs), this would represent a mean loss of approximately 24.2 kg (approximately 53 lbs) over roughly 11 months.

Notably, 100% of participants in the 8 mg and 12 mg groups achieved a clinically meaningful weight loss of at least 5% of body weight — a threshold associated with measurable improvements in metabolic health markers [1]. At 48 weeks, a substantial proportion of participants in the higher-dose groups achieved weight reductions of 20% or more, a level previously associated primarily with bariatric surgery outcomes.

Secondary Metabolic Findings

Beyond weight loss, the trial documented improvements in several cardiometabolic markers, including:

  • Reductions in waist circumference

  • Improvements in systolic blood pressure (up to 14.0 mmHg reduction in the 12 mg group)

  • Favourable changes in non-HDL cholesterol and triglycerides

  • Reductions in high-sensitivity C-reactive protein (hs-CRP), a marker of inflammation [1]

These secondary findings, while not primary endpoints of the trial, suggest that the weight loss observed with retatrutide is accompanied by broader metabolic improvements — consistent with findings seen with other GLP-1-class agents.

3.2 Phase 2 Type 2 Diabetes Trial (Rosenstock et al., The Lancet, 2023)

A parallel Phase 2 trial, published in The Lancet in August 2023, evaluated retatrutide in 281 adults with type 2 diabetes over 36 weeks [2]. Participants had a mean baseline HbA1c of 8.3% and a mean BMI of 35.0 kg/m². They were randomised to retatrutide at doses ranging from 0.5 mg to 12 mg, or to either dulaglutide 1.5 mg (an active comparator) or placebo.

Glycaemic Control

Retatrutide demonstrated substantial and dose-dependent reductions in HbA1c:

  • Maximum HbA1c reduction with retatrutide: approximately 2.2 percentage points from baseline in the highest-dose group

  • Dulaglutide comparator: approximately 1.4 percentage-point reduction

  • Placebo: approximately 0.3 percentage-point reduction [2]

An HbA1c reduction of 2.2 percentage points is considered clinically meaningful and exceeded what was observed with an established once-weekly GLP-1 receptor agonist in the same trial. For context, clinical guidelines generally consider a reduction of 1.0–1.5 percentage points as a meaningful threshold for pharmacological efficacy in type 2 diabetes management.

Weight Loss in Type 2 Diabetes

Participants with type 2 diabetes also experienced substantial weight loss, with the highest dose achieving a mean reduction of approximately 16.9% of body weight at 36 weeks — compared to approximately 2.0% with dulaglutide and 3.0% with placebo [2]. This is particularly notable because achieving meaningful weight loss in individuals with type 2 diabetes is often more challenging than in those without the condition, partly due to the effects of some diabetes medications on body weight.

No severe hypoglycaemia or deaths were reported during the trial, and the safety profile was generally consistent with the GLP-1 class of medications [2].

3.3 Phase 2a MASLD/Liver-Fat Substudy (Hartman et al., Nature Medicine, 2024)

A dedicated substudy, published in Nature Medicine in 2024, examined the effects of retatrutide on liver-fat content in a subset of participants from the Phase 2 obesity trial who had metabolic-dysfunction-associated steatotic liver disease (MASLD) — a condition formerly known as non-alcoholic fatty liver disease (NAFLD) — and a baseline liver-fat content of 10% or greater [3].

Liver Fat Reduction

The findings were among the most striking in the retatrutide research record:

  • In the 8 mg group: mean relative liver-fat reduction of approximately 82% from baseline at 48 weeks

  • In the 12 mg group: mean relative liver-fat reduction of approximately 86% from baseline at 48 weeks

  • 93% of participants in the 12 mg group achieved normal liver-fat levels (defined as less than 5% liver-fat content) at 48 weeks

  • 89% of participants in the 8 mg group achieved normal liver-fat levels at 48 weeks [3]

For comparison, even the most significant lifestyle interventions (such as sustained low-calorie diets preceding bariatric surgery) typically produce liver-fat normalisation in approximately 64% of individuals over a comparable timeframe [3].

These findings are of considerable interest because MASLD affects an estimated 20–25% of Canadian adults, and there are currently very few pharmacological options proven to significantly reduce hepatic steatosis. The glucagon receptor component of retatrutide's mechanism is believed to be a key driver of its hepatic effects, as glucagon receptor activation is known to stimulate hepatic fat oxidation [3].

A dedicated Phase 3 MASLD/MASH trial is currently underway, with results expected in 2026 [6].

3.4 Phase 3 TRIUMPH Programme: Emerging Evidence

The Phase 3 TRIUMPH (TRIple hormone receptor agonist for oUtcoMes in obeisty and overweigHt) clinical development programme represents the largest systematic evaluation of retatrutide to date. The programme is evaluating retatrutide across multiple Phase 3 trials including obesity, type 2 diabetes, obstructive sleep apnoea, knee osteoarthritis, and cardiovascular outcomes [6].

Topline results from TRIUMPH-1 (published May 2026) and TRIUMPH-2 and TRIUMPH-3 (published July 2026) have demonstrated continued and highly significant weight-loss outcomes at 80 weeks:

  • TRIUMPH-1 (12 mg dose, non-diabetic obesity): Mean weight reduction of approximately 28.3% from baseline at 80 weeks, with 65.3% of participants achieving a BMI below 30 kg/m² [7, 8]

  • These Phase 3 results, when published in full peer-reviewed form, will form a core part of any future regulatory submission

It should be noted that these Phase 3 topline results have been announced by Eli Lilly as press releases and are not yet fully peer-reviewed publications at the time of this article. They are cited here as preliminary evidence of the direction of the research programme and should not be interpreted as established clinical fact until peer-reviewed publication is complete.

4. The 10 mg Vial: A Strength Reference, Not an Established Dose

Readers who have encountered retatrutide in the context of a 10 mg vial should understand that a vial strength is a manufacturing and concentration specification — it indicates how much active peptide is contained within the vial as packaged. It does not correspond to any specific therapeutic dose that has been tested, validated, or established as safe or effective in clinical trials.

The Phase 2 obesity trial tested doses of 1 mg, 4 mg, 8 mg, and 12 mg once weekly [1]. The Phase 2 diabetes trial tested doses of 0.5 mg through 12 mg [2]. The Phase 3 TRIUMPH programme is primarily evaluating 4 mg, 9 mg, and 12 mg doses [6, 7, 8]. None of these protocols used a 10 mg dose as a studied or validated treatment dose.

A vial containing 10 mg of a peptide may be configured to allow dosing across a range — for example, a clinical formulation might be drawn to deliver various volumes corresponding to various doses — but the vial strength itself carries no clinical meaning regarding efficacy, safety, or appropriate use. Any interpretation of a "10 mg vial" as representing a specific treatment dose or a validated quantity for human administration would be medically and scientifically inaccurate.

5. Regulatory Status in Canada: What Health Canada Has and Has Not Authorised

5.1 Retatrutide Is Not Authorised for Sale in Canada

As of the date of this article, retatrutide has not been authorised by Health Canada for sale as a therapeutic product for any medical condition in Canada [4, 9]. This means it has not undergone Health Canada's New Drug Submission (NDS) review process, and no Notice of Compliance (NOC) has been issued for retatrutide.

Health Canada's drug authorisation process requires a sponsor (in this case, Eli Lilly) to submit comprehensive data from all clinical trials, preclinical studies, and manufacturing quality assessments. Health Canada's scientists and medical reviewers independently evaluate this data package to determine whether the benefit-risk profile of the drug is acceptable for the Canadian population. This process has not been completed for retatrutide.

5.2 What "Investigational" Means in Canada

Under Canada's Food and Drug Regulations, Part C, Division 5, a drug may only be sold or imported for the purposes of a clinical trial if a Clinical Trial Application (CTA) has been submitted to and reviewed by Health Canada [9]. Investigational drugs are used under closely controlled conditions — specific trial protocols, registered trial sites, qualified investigators, and participant consent processes — precisely because their safety and efficacy profile has not yet been fully characterised.

The clinical trial evidence summarised in this article was generated in this context: in registered, protocol-governed trials where participants were carefully selected, monitored, and followed by clinical teams. The findings represent the drug's behaviour under those controlled conditions and cannot automatically be generalised to broader populations or to use outside of a clinical trial framework.

5.3 No Regulatory Approval Is a Guarantee of Future Approval

The existence of positive clinical trial data, including the substantial Phase 2 and emerging Phase 3 results described in this article, does not guarantee that Health Canada will authorise retatrutide for marketing in Canada. Regulatory review may identify safety signals, data gaps, manufacturing concerns, or benefit-risk considerations that alter the path to authorisation. Consumers should not assume that promising trial results translate directly or inevitably into an approved treatment.

6. Risks, Side Effects, and Contraindications

Understanding the potential risks of an investigational drug is as important as understanding its potential benefits. The following summarises what clinical trials and pharmacological analysis have found regarding retatrutide's safety profile to date. Because retatrutide has not yet been fully reviewed by Health Canada, definitive contraindications have not been finalised, and the considerations below reflect a combination of established trial findings, class-based considerations extrapolated from related approved drugs, and theoretical concerns awaiting further data.

6.1 Gastrointestinal Adverse Effects (Established in Trials)

The most commonly reported adverse effects across all retatrutide clinical trials were gastrointestinal in nature. These are consistent with the GLP-1 receptor agonist class of medications and are believed to arise primarily from the slowing of gastric emptying and the direct effects of GLP-1 receptor activation on the gastrointestinal tract [1, 2, 5].

Reported gastrointestinal adverse effects include:

  • Nausea: Reported in 14–60% of trial participants at active doses, compared to lower rates in placebo groups. Most cases were classified as mild to moderate in severity.

  • Vomiting: Reported in 3–26% of trial participants at active doses.

  • Diarrhoea: Reported in 9–33% of trial participants across dose levels.

  • Constipation: Reported less frequently but observed across dose groups.

  • Abdominal discomfort and dyspepsia: Observed at rates not significantly different from placebo in some analyses [1, 2, 5].

These effects were most commonly reported during the dose-escalation phase of treatment — the period when dose is gradually increased — and tended to diminish over time as participants reached and maintained a stable dose. Discontinuation due to gastrointestinal adverse effects occurred in approximately 6–16% of treated participants depending on dose level [5].

6.2 Delayed Gastric Emptying

GLP-1 receptor agonism slows the rate at which the stomach empties its contents into the small intestine. This effect contributes to the appetite-suppressing action of the drug but also has clinical implications beyond the gastrointestinal symptoms described above. Delayed gastric emptying can:

  • Affect the absorption of other oral medications, potentially altering their onset of action and effective dosage

  • Complicate anaesthesia if a patient undergoes surgical procedures without an adequately extended pre-operative fasting period

  • Contribute to nausea, bloating, and a sense of early fullness [1, 5]

These considerations are important for individuals who take other oral medications, particularly those with narrow therapeutic windows, and for anyone undergoing any form of surgical or medical procedure.

6.3 Dehydration and Kidney Injury

Nausea and vomiting associated with GLP-1-class medications can lead to reduced fluid intake and fluid loss, creating a risk of dehydration. Dehydration in turn can impair kidney function, a risk that is particularly relevant for individuals with pre-existing kidney disease or those taking medications that affect kidney perfusion (such as NSAIDs, diuretics, or certain blood-pressure medications). This risk has been observed across the GLP-1 receptor agonist class and is considered a class-related concern for retatrutide based on its shared mechanism [5].

6.4 Hypoglycaemia in the Context of Diabetes Medications

Retatrutide stimulates insulin secretion in a glucose-dependent manner — meaning it only triggers insulin release when blood glucose is elevated, which theoretically minimises hypoglycaemia risk when used alone. In the Phase 2 diabetes trial, no severe hypoglycaemia was reported [2].

However, when used in combination with other glucose-lowering medications — particularly insulin or sulfonylureas — the combined effect can increase the risk of blood glucose falling to dangerously low levels. This is an important consideration for individuals with type 2 diabetes who manage their condition with multiple medications. This concern is class-based and well established for GLP-1 receptor agonists, and is expected to apply to retatrutide pending confirmation in ongoing trials.

6.5 Pancreatitis (Observed in Trials; Class Concern)

One case of acute pancreatitis was reported in the Phase 2 obesity trial [5]. Pancreatitis — inflammation of the pancreas — is a known class-level concern for GLP-1 receptor agonists, though whether the drugs directly cause pancreatitis or whether the association is mediated by obesity-related risk factors (which are independently associated with pancreatitis) remains a subject of scientific debate.

The current clinical trial evidence for retatrutide does not establish a clear causal relationship between retatrutide and pancreatitis, but the single reported case in a Phase 2 trial, combined with the class-level concern, means this remains an area of monitoring in ongoing Phase 3 trials. Individuals with a personal or family history of pancreatitis are typically excluded from retatrutide trials, and pancreatitis is likely to represent a contraindication or at minimum a strong precaution pending finalisation.

6.6 Gallbladder Disease (Class Concern)

Rapid and substantial weight loss — of the magnitude seen with retatrutide — is independently associated with an increased risk of gallstone formation and gallbladder disease. This relationship is well established and is related to changes in bile composition that occur during rapid fat loss. GLP-1 receptor agonists have also been associated with gallbladder adverse events in the trial records of approved drugs such as semaglutide and tirzepatide.

Phase 3 trials of retatrutide are actively monitoring gallbladder events, but the full characterisation of this risk specific to retatrutide requires completion of the longer-duration Phase 3 trial follow-up [6, 7, 8].

6.7 Allergic and Hypersensitivity Reactions

As with all injectable biological or peptide-based compounds, there is a potential for local injection-site reactions (such as redness, swelling, or discomfort at the site of injection) and, rarely, systemic hypersensitivity or allergic reactions. These have been reported in GLP-1 receptor agonist trials across the class and are expected to be a monitoring consideration for retatrutide, though the trial record does not currently highlight hypersensitivity as a prominent safety signal specific to this molecule.

6.8 Possible Thyroid C-Cell Tumour Risk (Theoretical; Not Established in Humans)

This is perhaps the most discussed theoretical concern associated with GLP-1 receptor agonist medications. In rodent studies conducted during the preclinical development of GLP-1 receptor agonists, high-dose, long-duration exposure was associated with an increased rate of thyroid C-cell hyperplasia and medullary thyroid carcinoma (MTC) — a rare form of thyroid cancer.

It is critical to understand the important distinctions here:

  • This finding has been observed in rats and mice, not in humans. The relevance of rodent thyroid physiology to human thyroid physiology for this specific mechanism is subject to ongoing scientific debate.

  • No cases of medullary thyroid carcinoma have been reported in retatrutide clinical trial participants based on the published record.

  • This concern is class-based, having been identified across GLP-1 receptor agonist medications, and retatrutide's trial protocols exclude participants with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2) as a precautionary measure [1, 2, 5].

Based on the exclusion criteria applied in clinical trials and by analogy to the established contraindication profile of related approved drugs, it is anticipated — though not yet finalised — that retatrutide's contraindication profile will include:

  • Personal or family history of medullary thyroid carcinoma

  • Personal or family history of Multiple Endocrine Neoplasia syndrome type 2 (MEN-2)

  • History of pancreatitis

  • Pregnancy and breastfeeding (based on standard practice for this drug class and the absence of safety data in these populations) [5]

These represent anticipated contraindications based on the evidence available and analogy to related authorised drugs. They are not finalised, as Health Canada has not completed a full regulatory review of retatrutide's safety data package.

6.9 Summary of Known and Anticipated Safety Signals

Safety Concern Evidence Status Source
Nausea, vomiting, diarrhoea, constipation Established in Phase 1, 2, and 3 trials [1, 2, 5]
Delayed gastric emptying Class-established; consistent with mechanism [1, 5]
Dehydration/kidney injury Class-level concern; mechanistically linked [5]
Hypoglycaemia with concomitant diabetes medications Class-established; not observed as isolated finding [2, 5]
Pancreatitis One case in Phase 2 trial; class concern [5]
Gallbladder disease Class concern; active Phase 3 monitoring [6, 7, 8]
Allergic/injection-site reactions Class-level; not prominent in current trial record [5]
Thyroid C-cell tumour risk Rodent finding; theoretical in humans; not observed in trials [1, 2, 5]

7. Evidence Limitations: What the Clinical Trial Record Does and Does Not Tell Us

The body of evidence for retatrutide, while promising and scientifically rigorous within its scope, carries important limitations that consumers should understand before drawing conclusions about this investigational peptide.

Duration: The most detailed safety and efficacy data available comes from 48-week (Phase 2) and 80-week (Phase 3 topline) trials. The long-term effects of retatrutide — over years or decades — are not yet known. Weight-regain patterns following discontinuation, long-term cardiovascular outcomes, and chronic-use tolerability remain under investigation.

Population specificity: Clinical trial participants are not representative of the full Canadian population. Trials typically exclude individuals with certain medical conditions, those taking certain medications, pregnant and breastfeeding individuals, older adults with multiple comorbidities, and others. The results may not predict outcomes for all individuals equally.

Dose range studied: The clinical trial record covers doses from 0.5 mg to 12 mg once weekly. A 10 mg vial is a product strength that does not correspond to any dose that has been systematically studied as a primary trial arm. Conclusions drawn from clinical trial data cannot be applied to dose or strength configurations that were not themselves the subject of controlled investigation.

Phase 3 data are preliminary: The Phase 3 TRIUMPH results referenced in this article are topline announcements from press releases and have not, at the time of writing, been fully published in peer-reviewed journals. They provide a directional signal about retatrutide's performance in larger and longer studies, but should not be treated as established clinical fact until peer-reviewed analysis is complete and available.

No head-to-head comparisons with all approved agents: The Phase 2 diabetes trial included dulaglutide as an active comparator, but no trials have directly compared retatrutide to semaglutide or tirzepatide under equivalent conditions and follow-up durations. Cross-trial comparisons are methodologically problematic and should not be made with confidence.

Regulatory review is independent of trial results: Positive trial data does not ensure regulatory authorisation. Health Canada's review process is independent and may identify additional questions, safety concerns, or data requirements.

8. Conclusion

Retatrutide represents one of the most scientifically compelling investigational molecules in the field of metabolic medicine. Its triple-receptor mechanism is biologically rational, its Phase 2 results are among the most striking in the weight-management research literature, and its emerging Phase 3 data suggest these early findings are durable and reproducible at scale.

The evidence summarised in this article — a 24.2% mean weight reduction at 48 weeks in the 12 mg Phase 2 obesity group versus 2.1% in the placebo group [1]; an approximately 2.2 percentage-point maximum HbA1c reduction in the Phase 2 diabetes trial [2]; and profound hepatic fat reductions in the Phase 2a MASLD substudy [3] — places retatrutide in a category of its own within the current landscape of investigational weight-management therapeutics.

At the same time, retatrutide has not been authorised by Health Canada as a marketed treatment. Its safety profile, while broadly consistent with the GLP-1 receptor agonist class and not marked by any unexpected serious signals in the Phase 2 record, continues to be characterised through ongoing Phase 3 trials. The anticipated contraindications are not yet finalised, the long-term safety data are not yet available, and the regulatory process in Canada has not yet been completed or, to the knowledge of the author, formally initiated.

Canadians who are interested in retatrutide, whether as patients, caregivers, or informed health consumers, should engage with this information as part of a broader conversation with a qualified healthcare provider. This article is intended to support that conversation with accurate, citation-backed information — not to substitute for individualised medical advice.

Educational Disclaimer

This article is intended solely for educational and informational purposes and does not constitute medical advice, a clinical recommendation, or an endorsement of any specific product, service, or therapeutic approach. The information presented is based on peer-reviewed clinical trial publications and publicly available regulatory information current as of the date of publication.

Retatrutide is an investigational drug. It has not been authorised by Health Canada for sale or use as a therapeutic treatment for any medical condition in Canada. The clinical trial findings described in this article were obtained under controlled experimental conditions and may not predict outcomes for any specific individual.

A 10 mg vial strength is a manufacturing specification and does not represent a validated, evidence-based therapeutic dose. No dosing recommendations are provided or implied in this article.

This article does not provide dosing instructions, injection guidance, administration advice, or any recommendation regarding the acquisition or use of retatrutide. Any decision regarding medication use should be made in consultation with a licensed healthcare provider who is familiar with your individual medical history.

If you have questions about your weight, metabolic health, or current or emerging treatment options, please speak with your primary care physician, endocrinologist, or another qualified Canadian healthcare professional.

Appendix: Sources

[1] Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-hormone-receptor agonist retatrutide for obesity — a Phase 2 trial. New England Journal of Medicine. 2023;389(6):514–526.
DOI: 10.1056/NEJMoa2301972 | PMID: 37366315

[2] Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, Phase 2 trial conducted in the USA. The Lancet. 2023;402(10401):529–544.
DOI: 10.1016/S0140-6736(23)01053-X | PMID: 37385280

[3] Hartman ML, Sanyal AJ, Loomba R, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomised Phase 2a trial. Nature Medicine. 2024.
PMID: 38858523 | Available via PubMed Central: PMC11271400

[4] Public Health Agency of Canada. Obesity in Canada — A Whole-of-Society Approach for a Healthier Canada. Government of Canada. Available at: https://www.canada.ca/en/public-health/services/publications/healthy-living/obesity-canada-whole-society-approach-healthier-canada.html

[5] Rotroff DM, Niswender KD, et al. The "Weight" for a New Agent Is Almost Over: A Commentary on the Novel Triagonist Retatrutide for Obesity. PMC (National Center for Biotechnology Information). 2024.
PMC Reference: PMC11536522

[6] ClinicalTrials.gov. A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight (TRIUMPH-1). Identifier: NCT05929066.
Available at: https://clinicaltrials.gov/study/NCT05929066

[7] Eli Lilly and Company. Lilly's Triple Agonist, Retatrutide, Delivered Powerful Weight Loss in Pivotal Phase 3 Obesity Trial (TRIUMPH-1 Topline Results). Press Release. 21 May 2026.
Available at: https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss-in-pivotal-phase-3-obesity-trial-302778859.html

[8] Eli Lilly and Company. Lilly's Triple Agonist, Retatrutide, Successful in Two Additional Phase 3 Obesity Trials, Delivering Significant Improvements in Weight and A1C (TRIUMPH-2 and TRIUMPH-3 Topline Results). Press Release. 23 July 2026.
Available at: https://www.drugs.com/clinical_trials/lilly-s-triple-agonist-retatrutide-successful-two-additional-phase-3-obesity-trials-delivering-22523.html

[9] Health Canada. Guidance Document: Part C, Division 5 of the Food and Drug Regulations — Drugs for Clinical Trials Involving Human Subjects (GUI-0100). Government of Canada.
Available at: https://www.canada.ca/en/health-canada/services/drugs-health-products/compliance-enforcement/good-clinical-practices/guidance-documents/guidance-drugs-clinical-trials-human-subjects-gui-0100/appendices.html

Word count: approximately 4,800 words (excluding appendix and tables)
All sources verified as of date of publication. Clinical trial data are current as of Phase 3 topline announcements available July 2026. Peer-reviewed Phase 3 publications are pending.

Back to blog